A Bitter Pill For Brand Names?
With its recent ruling in PLIVA Inc. v. Mensing,[1] the U.S. Supreme Court certainly gave generic prescription drug manufacturers plenty to celebrate. The 5-4 decision concluded that federal law preempts inadequate...To view the full article, register now.
Already a subscriber? Click here to view full article